Abstract
Fourteen patients with previously treated, locally advanced/metastatic transitional cell carcinoma (TCC) of the bladder or ureter received paclitaxel at a dose of 200 mg m-2 administered as a 3-h infusion every 21 days. The activity of paclitaxel in this group of patients was modest. The response rates were one partial response (PR) (7%) and three stable disease (SD). There were two early deaths.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Eisenhauer E. A., ten Bokkel Huinink W. W., Swenerton K. D., Gianni L., Myles J., van der Burg M. E., Kerr I., Vermorken J. B., Buser K., Colombo N. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994 Dec;12(12):2654–2666. doi: 10.1200/JCO.1994.12.12.2654. [DOI] [PubMed] [Google Scholar]
- McGuire W. P., Rowinsky E. K., Rosenshein N. B., Grumbine F. C., Ettinger D. S., Armstrong D. K., Donehower R. C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989 Aug 15;111(4):273–279. doi: 10.7326/0003-4819-111-4-273. [DOI] [PubMed] [Google Scholar]
- Murphy W. K., Fossella F. V., Winn R. J., Shin D. M., Hynes H. E., Gross H. M., Davilla E., Leimert J., Dhingra H., Raber M. N. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 1993 Mar 3;85(5):384–388. doi: 10.1093/jnci/85.5.384. [DOI] [PubMed] [Google Scholar]
- Rangel C., Niell H., Miller A., Cox C. Taxol and taxotere in bladder cancer: in vitro activity and urine stability. Cancer Chemother Pharmacol. 1994;33(6):460–464. doi: 10.1007/BF00686501. [DOI] [PubMed] [Google Scholar]
- Roth B. J., Dreicer R., Einhorn L. H., Neuberg D., Johnson D. H., Smith J. L., Hudes G. R., Schultz S. M., Loehrer P. J. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 1994 Nov;12(11):2264–2270. doi: 10.1200/JCO.1994.12.11.2264. [DOI] [PubMed] [Google Scholar]
- Scher H. I., Norton L. Chemotherapy for urothelial tract malignancies: breaking the deadlock. Semin Surg Oncol. 1992 Sep-Oct;8(5):316–341. doi: 10.1002/ssu.2980080511. [DOI] [PubMed] [Google Scholar]
- Seidman A. D. The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res. 1995 Mar;1(3):247–256. [PubMed] [Google Scholar]